The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.25
Bid: 42.00
Ask: 42.50
Change: 0.25 (0.60%)
Spread: 0.50 (1.19%)
Open: 42.25
High: 42.25
Low: 41.20
Prev. Close: 42.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exclusive Long Term Agreement Secured in China

27 Apr 2020 07:00

RNS Number : 8804K
Venture Life Group PLC
27 April 2020
 

27 April 2020

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

New, Exclusive Long Term Agreement Secured in China

Largest ever contract win for a minimum of €168 million 

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that it has signed a new, exclusive 15 year agreement with its existing Chinese partner for Dentyl. The agreement is for the distribution of products in Greater China (China, Macau, Hong Kong, Taiwan), and covers a number of the Group's products, including Dentyl.

 

This significant long term agreement has minimum purchase obligations to the value of €168m over the 15 year term. The Directors believe that this minimum value commitment, which the partner is required to purchase in order to retain the exclusive distribution rights, demonstrates our partner's long term intention and support for these important brands.

 

As announced on 9th April 2020, Venture Life has already received orders from this Chinese partner for Dentyl and some other key products in excess of €7m for delivery in 2020. At the start of 2020, the partner started a new marketing initiative and, coupled with heavy advertising investment by them, demand has increased rapidly, both pre and post the COVID-19 situation in China. Our partner largely sells our products via the online channel and all sales and marketing costs are borne by them, which aligns with our international corporate brands strategy.

 

Jerry Randall, CEO of Venture Life, commented: "I am absolutely delighted that we have secured this significant agreement in China with one of our key partners. The relaunch of Dentyl by our partner using online stores and channels has gained momentum quickly, and this significant extension of the agreement, both in time and minimum purchase commitment, shows the strength of both our future expectations for these products in China."

 

This announcement contains price sensitive information.

 

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

 

Cenkos Securities plc (Nomad and Broker)

 

+44 (0) 20 7397 8900

Stephen Keys / Mark Connelly / Cameron MacRitchie (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

Alma PR

venturelife@almapr.co.uk or + 44 (0) 203 405 0208

Helena Bogle / Hilary Buchanan / Kieran Breheny

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRFLFLRSSIRFII
Date   Source Headline
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:31 pmRNSResults of AGM
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.